We have investigated the signaling properties of the fibroblast growth factor (FGF) receptor substrate 3 (FRS3), also known as SNT-2 or FRS2β, in neurotrophin-dependent differentiation in comparison with the related adapter FRS2 (SNT1 or FRS2α). We demonstrate that FRS3 binds all neurotrophin Trk receptor tyrosine kinases and becomes tyrosine phosphorylated in response to NGF, BDNF, NT-3 and FGF stimulation in transfected cells and/or primary cortical neurons. Second, the signaling molecules Grb2 and Shp2 bind FRS3 at consensus sites that are highly conserved among FRS family members and that Shp2, in turn, becomes tyrosine phosphorylated. While FRS3 over-expression in PC12 cells neither increases NGF-induced neuritogenesis nor activation of Map kinase/AKT, comparable to previous reports on FRS2, over-expression of a chimeric adapter containing the PH/PTB domains of the insulin receptor substrate (IRS) 2, in place of the PTB domain of FRS3 (IRS2-FRS3) supports insulin-dependent Map kinase activation and neurite outgrowth in PC12 cells. Collectively, these data demonstrate that FRS3 supports ligand-induced Map kinase activation and that the chimeric IRS2-FRS3 adapter is stimulating sufficient levels of activated MapK to support neurite outgrowth in PC12 cells.
Introduction
The neurotrophin family of growth factors, nerve growth factor (NGF), brain-derived neurotrophin factor (BDNF) and neurotrophin-3 (NT-3), promote the survival, proliferation and differentiation of specific neuronal populations in the developing and mature nervous system [1] [2] [3] . Two distinct families of cell surface receptors mediate these cellular effects: the p75 neurotrophin receptor and the Trk family of receptor tyrosine kinases (RTKs). While p75 regulates a variety of cellular responses such as apoptosis, myelination and neurite outgrowth [4, 5] , the Trks, including TrkA (which binds NGF and NT-3), TrkB (which binds BDNF and NT-4/5) and TrkC (which binds NT-3), regulate signaling events underlying neuronal survival, proliferation, differentiation as well as a variety of physiological properties in the developing and adult nervous systems [1, 6, 7] .
How Trk RTKs integrate and propagate neurotrophic signals at the molecular level has been a topic of intensive study. Available evidence indicates that Trks conform to a standard model of RTK activation and signal transmission. In this model, dimerization of RTK monomers and subsequent trans-phosphorylation of multiple intracellular tyrosine residues stabilizes the kinase domain in an active conformation and generates binding sites which enable the direct recruitment of intracellular proteins containing SH2 or PTB domains [8] . In turn, these proteins orchestrate signaling events by activating various intracellular signaling cascades [9] .
Many different SH2 and PTB domain containing proteins have been shown to bind directly to Trk receptors and to participate in neurotrophic signal transduction (reviewed in refs. [1, 10] . Of these proteins, the PTB domain containing adapter protein FRS2 has emerged as an important mediator of neurotrophic signaling [11] . In PC12 cells [12] , NGF-dependent neurite extension is not observed in the absence of FRS2 tyrosine phosphorylation [11, 13] . Moreover, a direct link between FRS2 and neurite outgrowth in PC12 cells was shown by replacement of the native PTB domain with that of the insulin receptor substrate-1. Expression of this chimerical protein in PC12 cells was sufficient to convert insulin from a mitogenic to a differentiative agent [14] . Finally, a TrkA mutant showing a decreased ability to bind FRS2 is defective in its ability to drive neurite outgrowth, however, FRS2 overexpression in cells expressing this mutant can reconstitute NGF-dependent cell cycle arrest and differentiation [15] . These results suggest that FRS2 activation is sufficient to organize/ scaffold the signaling events required for NGF-dependent mitotic arrest and neuronal differentiation in vitro.
A second member of the FRS adapter protein family also exists, namely FRS3, or FRS2β [16] . These two proteins share a similar structural architecture overall, but initially appear to be quite divergent, sharing only 48% amino acid sequence identity and occupying separate chromosomal loci [17] . Analysis of the expression patterns of FRS2 and FRS3 during embryonic development reveals that FRS3 is expressed predominantly in developing neuroepithelium while FRS2 is expressed in multiple tissues [18, 19] .
Several lines of evidence, however, suggest overlapping functions of FRS2 and FRS3 in mediating cellular responses. A high degree of sequence identity lies within the N-terminal PTB domain (74%) and the C-terminal 30 residues (86%; [17] . A comparison of human, mouse and Xenopus FRS2 and FRS3 reveals five conserved sequence motifs (Fig. 1A ) [17] : (1) an Nterminal (MGXXXS) myristylation site required for plasma membrane targeting, (2) an N-terminal phosphotyrosine binding (PTB) domain that is involved in RTK binding [11, 20] , (3) three (in FRS3) or 4 (in FRS2) consensus (p)Y-X-N, Grb2-SH2 domain binding sites, (4) two consensus (p)Y-I/V-X-V/I/L/P, Shp2-SH2 domain binding sites and (5) the C-terminal 30 amino acids which, in FRS2, is important in SOS recruitment and long-term MAPK/ERK activation [14] . Like FRS2, FRS3 binds both the FGF and Trk receptors [16, 21] and ectopic expression of FRS3 in FRS2 null fibroblasts reconstitutes MAP kinase activation by FGF [19] . Finally, both FRS2 and FRS3 bind the small GTPase Rnd1, which is involved in the suppression of Rho activity in FGF activated PC12 cells [22] .
With the exception of a recent study detailing the binding of FRS3 to the small GTPase Rnd1 [22] little attention has been paid to the signaling properties of FRS3. Interestingly, Rnd1 binds the carboxyl-terminal region of both FRS2 and FRS3 and is dissociated in response to FGF-dependent Shp2 recruitment [22] . Since siRNA-mediated knockdown of Rnd1 in PC12 cells negated the positive effect of FGF on neurite outgrowth [22] , the authors conclude that one function of FRS3 is that of a cytoplasmic anchor for Rnd1, and upon phosphorylation by the FGFR1 exchanges Rnd1 for Shp2 allowing for the suppression of Rho by Rnd1 [22] . Despite the compelling nature of these results, the siRNA data in PC12 cells fails to differentiate between FRS2 and FRS3. In this study, we further clarify the role of FRS3 in neurotrophic signal transduction. We demonstrate that FRS3 binds TrkA at pTyr 499 and is a substrate of the Trk kinase. Tyrosine-phosphorylated FRS3 recruits both Grb2 and Shp2 and recruitment of these proteins are absolute requirements for the induction of neurite outgrowth in PC12 cells. Unlike FRS2 [20] , however, over-expression of FRS3 in PC12 cells does not enhance NGF-induced MAPK/ERK and/or AKT phosphorylation above levels observed in controls. Consequently, FRS3 over-expression in PC12 cells does not enhance NGF-induced neuritogenesis compared to NGF-treated PC12 cells alone. Lastly, we demonstrate that FRS2 and FRS3 show differential binding of the cell cycle regulators Cks1 and Cks2.
Materials and methods

Reagents
All reagents were from Bio-Shop and Sigma unless otherwise indicated. All PCR reactions utilized either Platinum Taq (Invitrogen) or Pfu Ultra (Stratagene). Tissue culture media (DMEM and Neurobasal) and antibiotics were from Invitrogen Inc. and Wisent, respectively. NGF, EGF and FGF-2 were from Harlan Bioproducts for Science. BDNF and NT-3 were the gifts of A.A. Welcher (Amgen Inc.). The D c protein assay kit was from Bio-Rad.
Antibodies
HRP conjugated anti-phosphotyrosine (RC20) and anti-Gal4 DNA Binding Domain (DBD) mouse monoclonal antibodies were from Transduction Labs and Santa Cruz Inc., respectively. Mouse anti-active-MAPK/ERK (BD-Bioscience), mouse anti-HA 3F10 (Roche Applied Science), rabbit anti-phosphoAKT (Ser ; G1466) antibodies were generated (GeneMed Synthesis) and affinity purified using standard techniques. The antimyc mouse monoclonal antibody (9E10) [23] was purified from ascites tumors grown in 4-6 weeks old Balb/c mice. HRP labeled secondary antibodies were from Jackson Immunoresearch.
Constructs
(i) FRS3 isolation: Human FRS3 was isolated from a fetal brain cDNA library (CLONTECH) using primers derived from the published SNT-2 sequence [16] that incorporated 5′ NcoI and 3′ SalI sites. A 1.5 kb PCR product was isolated and cloned into pCR2.1 (Invitrogen Inc.) to generate pCR2.1-hFRS3. (ii) Yeast-two Hybrid Vectors: Full-length FRS3 was subcloned from pCR2.1-hFRS3 into the EcoRI and SalI sites of pGEX-4T1 and then into the EcoRI and SalI sites of pGAD424 (CLONTECH) to generate pGAD424-hFRS3. hFRS2 was subcloned from pCR2.1-hFRS2 [11] , using the EcoRI and SalI sites, into pGAD424 and via the NcoI and SalI sites into pAS2.1. pAS2.1-rat TrkA ICD, rat TrkB ICD and rat TrkC ICD were constructed as described [24] . The pAS2.1-TrkA ICD -S3, -S8, -S9 and -S11B constructs have previously been described [13] . The S. pombe cell cycle regulatory gene, p13, was cloned as an EcoRI-BamHI fragment into pGAD424 and Cks1/Cks2 were amplified from a human brain cDNA library (Clontech) into the EcoRI/SalI sites of pGAD424. For in vitro pull down experiments, p13, Cks1 and Cks2 were cloned into the EcoRI/XhoI sites of pGEX-4T1. (iii) Expression vectors: MycHis tagged FRS3 was generated by PCR using 3′ primers incorporating a SalI site and deleting the termination codon. The 1.5-kb fragment was cloned into pCR2.1 to give pCR2.1-hFRS3ns (no stop) and then subcloned into the EcoRI and XhoI sites of pcDNA-MycHisA (Invitrogen Inc.) to generate pcDNA3.1-MycHisA-hFRS3. To create pcDNA3.1-MycHisC-FRS3-PTB domain, a 250-bp fragment encompassing the FRS3-PTB domain (a.a.1-79) was isolated from pCR2.1-hFRS3 using EcoRI and XhoI and sub-cloned into the EcoRI-XhoI sites of pcDNA3.1-MycHisC. (iv) FRS3 Point Mutations: Tyrosine to Alanine point mutation constructs were generated using the overlap extension mutagenesis procedure. PCR products (1.5 kb) were first TA cloned into pGEMT-EASY (Promega), digested with EcoRI/SalI and ligated into the EcoRI and XhoI sites of pcDNA3.1-MycHisA. FRS3 constructs for generating stable cell lines: the pBig3i bi-directional expression vector [25] was used in this study. pBig3i-hFRS3-MycHis was constructed by digesting the hFRS3-MycHis coding sequence, including the start and stop codons, from pcDNA3.1-MycHisA- FRS3 using EcoRI/PmeI and ligating this fragment into the EcoRI/EcoRV sites of pBig3i. All Trk constructs were in the vector pCMX.
The IRS2FRS2, IRS2FRS3 and IRS2FRS3-2A and 3A fusion proteins were constructed similarly to that described previously [14] . A murine IRS2 fragment encompassing the plekstrin homology (PH) and PTB domains (M 
137
-L 492 for FRS2 and FRS3, respectively), excluding the amino terminal PTB domains, were amplified by PCR and inserted in-frame with the IRS2 PH and PTB domains and the C-terminal myc tag. For both fusion proteins, the FRS portion was fused to the IRS2 region through an RP linkage. Chimerical proteins were targeted to the membrane by incorporating the K-ras C-terminal membrane targeting sequence KDGKKKKKKSRTRCTVM [26] Cterminal to the myc tag [16] 
Cell lines
Unless stated in the text, PC12, nnr5 and their derivative cell lines were maintained as previously described [13] . High Five insect cells were maintained in Grace's complete media containing 10% fetal bovine serum.
Cortical neurons
Cortical neurons were isolated from embryonic day 15 (E15) CD1 mice using a standard procedure with minor modifications as previously described [24] . Purified cortical neurons were plated onto 60 mm dishes (3 × 10 6 cell/each) pre-coated with 100 mg/ml poly-D-Lysine (Sigma) and were kept in culture for about 4 days. The medium was changed every 2 days. One hour prior to cell harvest, endogenous neurotrophins were removed by washing twice with HBSS. After stimulation with medium alone or NGF, BDNF, NT-3, EGF or bFGF (100 ng/ml, 5 min), cells were washed with cold phosphate-buffered saline containing 1 mM sodium orthovanadate and then lysed in ice-cold NP40 lysis buffer containing 1 mM sodium orthovanadate as described above.
Generation of PC12-FRS3 cell lines
PC12 cell lines stably expressing a reverse tetracycline Trans-Activator (rtTA)-FRS3 cassette were generated using the pBig3i vector [25] . Lipofectamine 2000 was the transfection vehicle and the cells were selected in 0.3 mg/ml hygromycin. Forty-eight clones were isolated and assayed for Doxycycline induced (2 μg/ml; 48 h) FRS3 expression by Western blotting using the anti-myc (9E10) antibody. Twelve independent lines were identified, three of which (FRS3-23, FRS3-27, and FRS3-48) were selected for further characterization due to the tight Dox-induced regulation of FRS3 expression.
Yeast two-hybrid
The AH109 yeast strain (CLONTECH) was used for all experiments. Yeast were co-transformed using the S.C. EasyComp kit (Invitrogen Inc.) following the manufacturer's instructions and plated onto -Leu /-Trp (-LT) plates to select for plasmid acquisition. Colonies were selected and re-plated onto -His / -Ade /-Leu /-Trp (-HALT) plates to select for positive interactions. Selfactivation was eliminated by the addition of 3-amino triazole (10-20 mM). Yeast lysates were generated from 2 ml overnight liquid cultures (-LT). Resuspended cell pellets in 1× SDS-PAGE sample buffer with 100 mM DTT were subject to three cycles of freeze-thaw followed by boiling. Debris was removed by centrifugation and expressed proteins assessed by SDS-PAGE.
Cell transfection, lysis, and protein concentration determination
COS-7 cells were transfected using the DEAE-Dextran protocol while Lipofectamine 2000 was used to transfect PC12 cells. Cell lysates were generated 48 h after transfection as described [11] and the protein concentration of clarified lysates determined using the D C protein assay.
Immunoprecipitations
Immunoprecipitations were carried out on equal amounts of total lysate protein as previously described [11] . Monoclonal antibodies were precipitated with 15 μl of Pansorbin and 15 μl of Gamma Bind Sepharose (Amersham Biosciences) while polyclonals were precipitated with 20 μl of Pansorbin. Washed pellets were re-suspended in 1× SDS-PAGE sample buffer, containing 100 mM DTT, and heated at 75°C for 5 min.
Western blotting
Protein samples separated by SDS-polyacrylamide gel electrophoresis were transferred onto Poly-Vinyl Di-Flouridine (PVDF) membranes (Bio-Rad) using a semi-dry transfer apparatus. Blotto (10% powdered milk in PBS/Tween) was employed as a blocking agent with all antibodies except for the antiphosphotyrosine and anti-active MAPK/ERK/AKT. For these antibodies, 2% BSA in 10 mM Tris [pH 7.5], 100 mM NaCl, 0.1% Tween 20 plus 1 mM sodium orthovanadate was used throughout. Relevant protein bands were detected using the Western Lightening Chemiluminescence kit (Perkin-Elmer).
Neurite response assay
Neurite response assays were performed in poly-D-lysine coated 24 well dishes. Cells were plated at 2000-3000 cells per well. Four separate treatment conditions were employed: (i) no Dox/no treatment; (ii) no Dox/+NGF; (iii) +Dox/−NGF; (iv) +Dox/+NGF. Cells were stimulated with Doxycycline (2 μg/ml) or vehicle (DMSO) for 48 h after which they were stimulated with NGF (20 ng/ml) for an additional 4 days. Fresh Doxycycline (2 μg/ml) and NGF (20 ng/ml) was added daily. Neurite response was defined as cells with processes greater than two cell body diameters in length. In all experiments (n = 3), 10 separate frames (550-800 cells) were counted per condition and converted into percentages. The levels of Dox-induced FRS3 expression was confirmed by Western blot analysis of whole cell lysates upon termination of the assay.
In vitro binding assays
Glutathione-S-transferase fusion proteins (GST-Cks1, GST-Cks2 and GSTp13 suc1 ) were expressed in E. coli strain BL21-DE3 RIL cells (Stratagene). The cells were lysed by sonication in PBS, pH 7.5 containing 2% Triton X-100, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 10 μg/ ml pepstatin, 1 mM EDTA and 1 mM PMSF and centrifuged at 20,000×g to remove insoluble debris. Fusion proteins were purified on glutathione-sepharose beads (Pharmacia) and resuspended in lysis buffer containing 1 mM DTT. Fusion proteins were quantified either by direct comparison to known amounts of BSA by SDS-PAGE or by elution from the glutathione-Sepharose with 50 mM reduced glutathione in 25 mM Tris-Cl, pH 7.5 with 137 mM NaCl, 1 mM EDTA and 10% glycerol, followed by dialysis against elution buffer without glutathione and quantified by direct protein assay. Insect cells expressing myc-tagged FRS2 and FRS3 were disrupted in NP-40 lysis buffer (see above) and assessed for protein. Pulldown experiments were performed using 1 μg of GST-fusion protein, comparable levels of insect cell lysates expressing FRS2, FRS3, FRS2 (PTB)FRS3, FRS3(PTB)FRS2, IRS2FRS2 and IRS2FRS3 and glutathione sepharose. Complexes were isolated by centrifugation, washed with PBS-Triton X100 containing protease inhibitors, and analyzed by SDS-PAGE/Western blotting using the anti-myc antibody 9E10.
Results
FRS3 binds the Trk family of neurotrophin receptors
The PTB domain of FRS3 has been reported to interact directly with the TrkA receptor [21] . To determine the possibility of differential interactions with the other members of the Trk family, we assayed for differences in interaction with TrkA, TrkB and TrkC using the yeast two-hybrid system. However, as shown in Fig. 1B , we found that full-length FRS3 bound comparably to the intracellular domains (ICDs) of TrkA, TrkB and TrkC. FRS2 binding to all three Trks served as a positive control [11] .
FRS2 binds to rat TrkA at phosphotyrosine residue 499 and requires integrity of the preceding amino acids, IMENPXY [11] . Therefore, we wished to determine if FRS3 bound the same residue in rat TrkA and if this interaction also required integrity of the NPQY motif. Full-length FRS2 and FRS3 were expressed in yeast along with either wild-type TrkA, and a series of TrkA mutants (Fig. 1C) [11, 27] , (iii) S9, a Y 794 F substitution that disrupts PLC-γ1 binding [27] and (iv) S11b, a kinase inactive K 547 A mutant. As shown in Fig. 1D , both FRS3 and FRS2 interact with wild type Trk and TrkA S9, but not with TrkA S11b or TrkA S8. These results indicate that FRS3 binds to TrkA following phosphorylation of tyrosine 499. Unlike FRS2, however, FRS3 retains binding to the TrkA S3 deletion mutant, suggesting a subtle difference in how these adapters interact with the ICD of the Trk receptors. Expression of all four mutant TrkA constructs was verified by Western blotting (Fig. 1E ).
FRS3 is tyrosine phosphorylated by FGF, NGF, NT-3 and BDNF but not EGF
It has previously been demonstrated that FRS3 is tyrosine phosphorylated in response to FGF in transfected fibroblasts [16] ; however, whether this is also true for neurotrophin stimulation has not been determined. To address this, we overexpressed FRS3/myc in COS-7 cells in the absence and presence of co-transfected TrkA. As a positive control, FRS2 was also assayed. As shown in Fig. 2A, FRS3 and FRS2 are tyrosine phosphorylated in response to NGF only when co-expressed with TrkA, suggesting that both FRS proteins are targets of the Trk kinase. Over-expressed FRS2 and FRS3 both run as a doublet on SDS-PAGE, the reasons for which are not entirely clear. Stripping and re-probing the blot reveals similar levels of FRS2 or FRS3 expression in the absence or presence of TrkA, however, FRS3 is expressed at much higher absolute levels as compared to FRS2. This difference in expression levels is independent of the cell line and the expression construct that is used. In addition, FRS2 consistently migrates slower on SDS-PAGE than FRS3 despite the 2 proteins having similar predicted molecular weights. This most likely reflects the fact that FRS2 is phosphorylated on multiple serine/threonine residues [19] .
Our observation that FRS3 interacts with all three Trk RTKs prompted us to examine the ability of these kinases to phosphorylate FRS3. As shown in Fig. 2B, FRS3 is tyrosine phosphorylated in response to NGF, BDNF and NT-3 when the cognate receptors for these ligands TrkA, TrkB and TrkC, respectively, are co-expressed. Kinase inactive receptors are unable to stimulate tyrosine phosphorylation of FRS3 (Fig. 2B  and data not shown) . Thus, FRS3, like FRS2, appears to be tyrosine phosphorylated by all members of the Trk family.
To examine the relationship between FRS3 and TrkA further, we generated three independent lines of PC12 cells overexpressing FRS3/myc under the control of a tetracycline inducible promoter. As shown in Fig. 3A, three cell lines (FRS3-23,  FRS3 -27, and FRS3-48) were selected based on tight induction of FRS3/myc expression in response to 48 h of Doxycycline (2 μg/ml) treatment (Fig. 3A, upper panel) . FRS3 was stably expressed even after 8 days of Dox stimulation (lower panel). Of note, the FRS3-23 cell line expressed much higher levels of FRS3/myc than clone 27 or 48. PC12 cells also express receptors for epidermal growth factor (EGF); however, as shown in Fig.  3B , only NGF and FGF stimulate FRS3 tyrosine phosphorylation in Dox-induced cells. These observations are consistent with the data presented in Fig. 2 and support a model of RTK specificity in the binding and tyrosine phosphorylation of FRS3.
To address the phosphorylation of endogenous FRS3 in primary neurons, we assayed mouse cortical neurons where FRS2 is tyrosine phosphorylated in response to BDNF and NT-3 [28, 29] . To facilitate this analysis, a polyclonal antibody was generated using an FRS3-specific peptide. Cortical neurons were isolated from E15 mouse embryos, cultured for 2-4 days in vitro and stimulated with NGF, BDNF or NT-3 for five min, then lysed and immunoprecipitated with anti-Trk or anti-FRS3 antibodies followed by blotting with an anti-phosphotyrosine antibody. As demonstrated in Fig. 3C , endogenous TrkB, TrkC and FRS3 are tyrosine phosphorylated in cortical neurons in response to BDNF and NT-3 stimulation. Stripping and re-probing the blots with anti-Trk or anti-FRS3 antibodies confirms the identity of the phosphotyrosine bands. Importantly, these observations demonstrate that endogenous FRS3 is a target of the Trk kinases in embryonic cortical neurons. Lastly, we also addressed the specificity of growth factor-induced tyrosine phosphorylation of FRS3. Similar to our results obtained in PC12 cells (Fig. 3B) , neurotrophin stimulation (BDNF), FGF and EGF all induce the tyrosine phosphorylation of their cognate RTKs while only BDNF and FGF, but not EGF, induce the tyrosine phosphorylation of FRS3 in embryonic cortical neurons (Fig. 3D) .
Neurotrophic activation of TrkA stimulates the co-immunoprecipitation of FRS3 with Grb2 and Shp2
Based on the amino acid sequence of FRS3 (Fig. 1A ) [17] , and previous observations with FRS2 [20, 30] , we predicted that both Grb2 and Shp2 would bind FRS3. As shown in Fig. 4A , this assumption is correct as both Shp2 and Grb2 co-immunoprecipitated with FRS3 in a NGF-dependent fashion. To investigate this in further detail, we constructed a series of FRS3 mutants in which the tyrosine residues within each of the consensus binding motifs were mutated to alanine (Fig. 4B ). These were then overexpressed in COS cells in conjunction with either wild-type TrkA or kinase dead TrkA S11b, stimulated with NGF, and subjected to anti-Myc immunoprecipitation. As shown in the upper panel of Fig. 4C 7) , and completely eliminated when using the isolated FRS3-PTB domain (lane 3), the FRS3- We also observed Grb2 to co-immunoprecipitate with FRS3 cells expressing wild-type, but not kinase dead, TrkA (Fig. 4C , middle panel; lanes 2 and 9). This co-immunoprecipitation was not observed with FRS3 containing triple alanine substitutions Fig. 5 . IRS2FRS2 and IRS2FRS3 chimerical proteins support insulin-dependent MAPK/ERK phosphorylation and neurite outgrowth and is dependent upon the integrity of the Grb2 and Shp2 binding sites. (A) nnr5-B5 cells were transfected the chimerical proteins IRS2/FRS2 and IRS2/FRS3 serum starved for 24-48 h as described in Materials and methods and stimulated for the indicated times with 10 μg/ml insulin. Lysates were prepared and analyzed for phospho-MAPK/ERK as described in Materials and methods. Activated MAPK/ERK was determined using the phospho-MAPK/ERK antibody (1:10,000) and the blots stripped and reprobed with the α-MAPK/ERK antibody (1:10,000). Expression of the IRS2 chimeras was determined using α-FRS2 and α-FRS3 antibodies (1:3000). (B) Nnr5-B5 cells were transfected with a control vector containing only the PTB domain of IRS2, IRS2FRS2 or IRS2FRS3, and stimulated with 10 μg/ml insulin. Neurite outgrowth was assessed after 48 h. (C) Nnr5-B5 cells stimulated with 10 μg/ml insulin or 100 ng/ml NGF were immunoprecipitated with an anti-phosphotyrosine antibody. Immune complexes were analyzed for TrkA with the anti-HA antibody, 3F10 (1:5000). (D) Nnr5-B5 cells were transfected with IRS2/FRS3-3A (Y192A; Y288A; Y323A) and IRS2/FRS3-2A (Y418A; Y456A), serum starved for 24-48 h and stimulated with 10 μg/ml insulin for the indicated times. Phospho-MAPK/ERK was detected as above and expression of IRS2FRS3 mutants was determined using an anti-FRS3 antibody (1:3000). (E) Nnr5-B5 cells expressing IRS2FRS3-2A and IRS2FRS3-3A were stimulated with insulin as described in (A). The cells were assessed for neurite outgrowth after 48 h. Although the results above suggest a degree of overlap in FRS2 and FRS3 signaling, we wanted to determine whether FRS3, upon activation, could induce prolonged MAPK/ERK activation and neurite outgrowth independently of those activated by endogenous FRS2 in PC12 cells. To detect potential activation of these pathways by FRS3, we generated a chimeric adapter in which the PTB domain of FRS3 was replaced with the PH/PTB domains of IRS2. This approach was employed previously [14] to demonstrate MAPK/ERK activation by FRS2 in response to insulin. Insulin typically stimulates lower, transient levels of MAPK/ERK activity and is mitogenic for PC12 cells. TrkA expressing nnr5 cells (B5) were transiently transfected with the IRS2/FRS2 or IRS2/FRS3 chimeras and assayed for insulin-induced MAPK/ERK activation as well as changes in differentiation/neurite outgrowth. To facilitate these studies, transfected cells were serum-starved for at least 24 h before stimulation with 10 μg/ml insulin [14] . We employed nnr5-B5 cells for these studies [13] as we found these cells to be highly transfectable and to display a high level of neurite outgrowth. A rapid (10 min) and sustained (12 h) increase in insulin-dependent MAPK/ERK phosphorylation was observed in both IRS2/FRS2 and IRS2/FRS3 expressing cells, a phenomenon not observed in control nnr5-B5 cells expressing only the IRS2 PTB and PH domains (Fig. 5A) . For reasons that are not clear, we consistently observed higher expression of IRS2/FRS2 than that of IRS2/FRS3 (Fig. 5A, lower panel) . In agreement with the results in Fig. 5A , nnr5-B5 cells expressing both IRS2/FRS2 and IRS2/FRS3 expressing cells undergo insulin-dependent neurite outgrowth (Fig. 5B) . However, process formation in IRS2/FRS3 expressing cells is more robust than that in IRS2/FRS2 expressing cells despite similar levels of MAPK/ERK phosphorylation (Fig. 5B) . TrkA phosphorylation occurred only in response to NGF indicating no indirect insulin-mediated activation of TrkA (Fig. 5C) .
The ability of FRS2 to facilitate FGF-dependent neurite outgrowth relies on the recruitment and activation of Shp2 [30] . Thus, we next assessed the relative importance of Grb2 and Shp2 binding to FRS3 in promoting MAPK/ERK activation and neurite outgrowth. Thus, IRS2/FRS3 chimeras with mutations at either the three Grb2 (Y194A, Y288A and Y323A) or the two Shp2 (Y418A and Y456A) binding sites were assayed for their ability to support insulin-dependent MAPK/ERK activation and neurite outgrowth in nnr5-B5 cells. No increase in insulindependent activation of MAPK/ERK, compared with the response observed with IRS2/FRS3 (Fig. 5A ), was noted with either mutant even after 24 h of insulin treatment (Fig. 5D, left  panel) . Similar levels of expression were observed for both mutants (Fig. 5D, right panel) . Accordingly, we also failed to observe any effect of insulin on neurite outgrowth in either of the IRS2/FRS3 mutant expressing nnr5-B5 cells (Fig. 5E) .
Over-expression of wild type FRS3 does not enhance NGF-dependent neuritogenesis
Over-expression of FRS2 in PC12 cells augments growth factor induced neurite outgrowth more than two-fold greater than that observed in the absence of growth factor [11, 30] . In addition, FRS2 over-expression facilitates NGF-induced mitotic arrest [15] . These effects are most likely a consequence of a higher level of MAPK/ERK activity observed upon overexpression of FRS2 [30] . Since the chimeric IRS2/FRS3 adapter stimulates prolonged MAPK/ERK activation in response to insulin, we determined if over-expression of FRS3 would similarly augment neurite outgrowth in PC12 cells.
Our PC12-FRS3 over-expressing lines were either treated with Doxycycline (2 μg/ml; 48 h), to induce FRS3 expression, or left untreated and stimulated with either vehicle or 20 ng/ml NGF. Fresh Dox and NGF were added daily. After 4 days of NGF treatment, neurite extension was scored by counting the percentage of cells containing neurites longer than two cell bodies. Ten frames (550-800 cells) from duplicate samples were scored. As shown in Fig. 6A , the percentage of NGF responsive PC12 cells, irrespective of Dox treatment, was approx. 10-12%. While the mean percentage of NGF- responsive cells in the FRS3 clones ranged from 5 to 10% in the absence of Dox, there was no change in the percent responsive cells in the presence of Dox stimulation. Dox-induced expression of FRS3 was confirmed by Western blot analysis in a parallel set of plates at the end of the assay (Fig. 6B) . Similar results were obtained in 3 independent assays.
3.6. Over-expression of FRS3 does not enhance NGF-induced MAPK/ERK/MAPK/ERK or Akt activation While FRS3 expression in PC12 cells did not increase the percentage of neurite bearing cells in response to NGF, we reasoned that if NGF-stimulation, via intrinsic pathways, already met threshold response levels, FRS3 over-expression may not significantly increase the absolute levels of detection. To address this possibility, we asked whether over-expression of FRS3 altered detectable levels of NGF-dependent MAPK/ERK or Akt activation. Over-expressing cell lines were either left untreated or treated with Doxycycline (2 μg/ml; 48 h), to induce FRS3 expression, and stimulated with either vehicle or NGF (2 ng/ml) for 15 min and 2 h. As shown in Fig. 7A , NGF stimulated a significant level of MAPK/ERK phosphorylation at 15 min and 2 h in parental PC12 cells that was not significantly affected by treatment with Dox (Fig. 7B) . All three Doxinducible cell lines exhibited NGF-dependent MAPK/ERK phosphorylation, however, we found no statistical difference in the absolute level of phospho-MAPK/ERK, at either time point (N = 3), between pairs of untreated and Dox treated cultures (Fig. 7A) . Similarly, no statistical difference in phospho-MAPK/ERK levels was seen when cells were incubated with NGF for 6 and 24 h (data not shown). Stripping the blots and reprobing with anti-MAPK/ERK demonstrated comparable levels of protein loading per lane. Importantly, the failure of Dox to influence NGF-dependent MAPK/ERK activity was not a consequence of lack of Dox-induced FRS3 expression in all lines (23, 27 and 48) (Fig. 7B) .
Using the same approach, we assayed for potential Dox/ FRS3-dependent changes in levels of phosphorylated Akt following 30 and 60 min of NGF (5 ng/ml) stimulation. As shown in Fig. 8 , Dox had no effect on the apparent levels of NGF-induced Akt phosphorylation at Ser 473 in parental PC12 cells. Similarly, in all three FRS3 clones, FRS3 over-expression did not increase the NGF-dependent levels of phosphorylated Akt, despite similar levels of protein loading per lane (n = 3). Again, densitometric analysis of the levels of phosphorylated Akt between the Dox treated and untreated pairs revealed no statistical differences.
FRS3 does not interact with yeast p13
suc1 or the orthologous mammalian Cks proteins FRS2 was originally identified by its ability to bind the yeast cell cycle regulatory protein, p13
Suc1 [20, 28, 31] , the mammalian orthologues of which are Cks1 and Cks2 [32] . Cks1 and Cks2 share 89% sequence identity while Cks1/2 share 50% sequence identity with p13 Suc1 (Fig. 9A) . Both Cks1 and Cks2 bind to the N-terminal region of FRS2 [33] with the binding site spanning the myristolation site into the PTB domain [33] . Previously, it had been reported that FRS3 does not bind p13
Suc1 [16] , raising the possibility that FRS3 similarly does not interact with Cks1 or Cks2.
To address the binding capacity of FRS2 and FRS3 with Cks1 and 2, we used the yeast two-hybrid system. Yeast were co-transformed with full-length FRS3 or FRS2 fused to the Gal4 DNA binding domain along with Cks1, Cks2 or the intracellular domain (ICD) of TrkA (as a positive control) fused to the Gal4 transactivation domain (TAD). We also included a Gal4 TAD-p13 suc1 fusion as a control. Yeast were transfected with the appropriate vectors and assessed for protein expression. All proteins were expressed to varying degrees in yeast (Fig.  9B ). Colonies were plated on selective HALT plates to assess protein interaction. Neither FRS2 nor FRS3 interacted with the activation domain of Gal4 alone, while both interacted with the positive control, TrkA (Fig. 9C) . Growth on HALT plates was observed for FRS2 and p13 suc1 , Cks1 and Cks2 indicating a positive interaction. In contrast, we observed no growth when FRS2 was replaced with FRS3, indicating a lack of interaction (Fig. 9C) .
We also performed an in vitro binding assay using p13 suc1 , Cks1 and Cks2 fused to glutathione-S-transferase (GST). The fusion proteins were expressed in E. coli, and used to precipitate myc tagged FRS2 and FRS3 over-expressed in baculovirus infected Sf9 insect cells. All three GST fusion proteins effectively precipitated FRS2 but not FRS3 (Fig. 10A,  lanes 1-4 and 6-9) . Again, FRS2 and FRS3 migrate at different rates on SDS-PAGE (Fig. 10A, compare lanes 5 and  10) . These data indicate that there are sufficient structural dissimilarities in the N-terminal regions of FRS2 and FRS3 to account for the differential binding of these adapters to the Cks proteins.
Our data suggest that the Cks1/FRS2 interaction is not essential for the induction of cell cycle arrest and differentiation in nnr5-B5. Indeed, the Cks1/FRS2 interaction was proposed to play a regulatory role in FGF-mediated mitogenesis [33] . To test this hypothesis we performed an additional in vitro binding assay using GST-Cks1/2 and IRS2/FRS2 expressed in insect cells to determine whether Cks1/2 could interact with the PH-PTB domain of the IRS2/FRS2 chimera. The results indicate that neither Cks1 nor Cks2 are able to precipitate IRS2/FRS2 (Fig. 10B, lower panel, lanes 1-4) indicating that IRS2/FRS2 and IRS2/FRS3 mediated insulin-dependent neurite outgrowth in nnr5-B5 cells occurs independently of Cks1/2 binding. We also looked at the interaction of Cks1/2 with chimerical FRS2 and FRS3 proteins in which we had swapped their respective PTB domains. Predictably, the FRS3(PTB)/FRS2 chimera was incapable of binding either Cks1 or Cks2 (Fig. 10B, lower  panel, lanes 6-9) ; however, we were surprised to observe a similar result with the FRS2(PTB)/FRS3 chimera (Fig. 10B,  lower panel, lanes 11-14) . These data suggest that either structural determinants beyond the PTB domain are also important in binding of Cks1/2 to FRS2 or that the structure of the FRS2/FRS3 chimera is inhibitory to Cks binding.
Moreover, the fact that p13 suc1 binds to IRS2/FRS2 and FRS3 (PTB)/FRS2, but not to FRS2(PTB)/FRS3, suggests that p13 suc1 binds FRS2 carboxy-terminal to the PTB domain.
Discussion
We present four lines of evidence supporting a role for the FRS3 adapter in neurotrophic signal transduction. First, FRS3 binds all three members of the Trk family of RTKs in a phosphotyrosine-dependent manner. Secondly, FRS3 is tyrosine phosphorylated in response to neurotrophic or bFGF but not EGF stimulation. Thirdly, upon tyrosine phosphorylation, FRS3 recruits Grb2 and Shp2, two known mediators of neurotrophic signaling downstream of the Trk receptors. Finally, a chimeric FRS3 protein in which the PTB domain was replaced with the PH and PTB domains of the Insulin Receptor Substrate 2 (IRS2) induced prolonged MAPK/ERK activity and neurite outgrowth in PC12 cells in response to insulin. This latter result is in agreement with those of Gotoh et al. [19] who showed that ectopic expression of FRS3 in FRS2 null fibroblasts reconstituted FGF-dependent MAPK/ERK phosphorylation. We have extended this observation to show that FRS3, similar to FRS2, is capable of stimulating prolonged MAPK/ERK activity and neurite outgrowth in PC12 cells, albeit using a chimerical suc1 were expressed and purified as described in Materials and methods. Bacculoviruses were generated with myc-tagged FRS2 and FRS3 and used to infect T. ni insects cells. Pulldown assays from insect cell lysates were performed as described in Materials and methods. Lanes 5 and 10 represent the assay input. (B) Bacculoviruses were generated with myctagged FRS3(PTB)FRS2, FRS2(PTB)FRS3 and IRS2FRS2 and used to infect insect cells. Pulldown assays were as described (Materials and methods). Lanes 5, 10 and 15 represent assay input. Proteins were detected using 9E10.
adapter activated through the insulin receptor. While we originally postulated that FRS3 over-expression in PC12 cells might significantly enhance NGF-dependent neurite outgrowth and MAPK/ERK-1/2 phosphorylation relative to controls, comparable to the effects of FRS2 [20] , this was not observed even when cells were assayed at low doses of NGF (2 ng/ml). This suggests that FRS3 over-expression uses different mechanisms to support ligand-dependent activation of MAPK/ERK in PC12 cells relative to FRS2.
While both FRS2 and FRS3 are tyrosine phosphorylated and bind Grb2 and Shp2 in response to NGF, we have observed differences that may directly affect the signaling events mediated by these two adapters. For example, both FRS2 and FRS3 bind TrkA at phosphotyrosine 499, FRS2 binds with a broader footprint as reflected in its decreased ability to interact with the S3 mutant in which the immediately upstream 493 IMENP 497 pentapeptide is deleted [11] . Conversely, FRS3 still binds the TrkA-S3 mutant suggesting a different binding conformation and/or interaction of FRS3 with TrkA as compared to FRS2. A similar observation has been made for FRS2 and FRS3 binding to the FGFR1 where FRS2 binds to a juxtamembrane region encompassing AAs 401-434 while FRS3 binding requires an additional C-terminal 17 amino acids, amino acids 401-451 [16] .
Similar to FRS2 [20, 30] , Grb2 and Shp2 also have important implications for FRS3 signaling; however, our data suggest subtle differences between FRS2 and FRS3 with respect to Grb2 and Shp2 binding, which may have effects on downstream signaling pathways. In this respect, FRS2 and FRS3 share three conserved Grb2 (Y192, 287 and 322 in FRS3 and Y196, 306 and 349 in FRS2) and two conserved Shp2 binding sites (Y436 and 471 in FRS2 and Y418 and 456 in FRS3), with FRS2 containing an additional Grb2 binding site at Y392 [20] . Elimination of all Grb2 sites in FRS3 abrogates Grb2 co-immunoprecipitation with FRS3 indicating that Grb2 is only recruited into a signaling complex directly. In contrast, Grb2 is recruited to FRS2 by direct binding as well as via binding to Shp2 [30] . While the direct implications of these differences are not immediately apparent, it may account for the observation that FRS2, but not FRS3, overexpression augments NGF-induced MAPK/ERK activation in PC12 cells.
Another difference between FRS2 and FRS3 concerns the ability of FRS2 but not FRS3 to bind Cks1 and Cks2, the mammalian orthologs of the yeast cyclin-dependent kinase binding protein p13 suc1 . Binding of FRS2 to p13 suc1 has been known for some time as the protein was originally identified by precipitation with p13 suc1 -agarose [28] . The binding of Cks1 and Cks2 to FRS2 is mediated through an N-terminal motif spanning the myristoylation site and extending into the PTB domain of FRS2 [33] . It was proposed that Cks1 binds to unphosphorylated FRS2 and is displaced upon FGFRmediated phosphorylation [33] . Displacement of Cks1, and its re-distribution into the nucleus, allows for the degradation of p27
Kip1 thereby permitting the cells to complete the G1/S transition [33] . Thus, the evidence suggests that the Cks1/ FRS2 interaction is an important regulator of FGF-mediated mitogenesis. Our data with the IRS2 chimeras suggest that the Cks1/FRS2 interaction is not obligatory to induce growth arrest and neurite outgrowth in nnr5-B5 cells. Indeed, the IRS2 PTB domain failed to recruit Cks1/2 in vitro. Moreover, FRS3 does not bind Cks1/2 but expression of FRS3 reconstitutes FGF-dependent MAPK/ERK activation in FRS2 −/− fibroblasts [19] .
Previous studies have shown that differentiation of PC12 cells may be induced by over-expression of signaling molecules resulting in prolonged MAPK/ERK activity (v-src [34] , ras [35] , the EGFR [36] and p21 [37] ). In spite of this, it is unlikely that our observations with IRS2/FRS3 reflect an overexpression artifact. For instance, neurite outgrowth is dependent upon insulin, in keeping with the chimeric nature of the proteins. Moreover, the response is not commensurate with the level of expression, since IRS2/FRS3 is expressed to a lesser extent than IRS2/FRS2 yet mediated a stronger cellular response. Rather, these studies provide a platform whereby the functional role of endogenous FRS3 during neuronal development can be delineated in either primary neurons or genetically engineered mouse models.
The differences in the spatio-temporal expression of FRS2 and FRS3 in embryonic development suggests that these proteins serve different roles in growth and development [18, 19] . In mitotic cells, phosphorylation of FRS2, by FGFR1, promotes the dissociation and nuclear re-distribution of Cks1 allowing the formation of a Cks1/Cdk/Cyclin/p27
Kip1 complex resulting in the subsequent degradation of p27 Kip1 , release of an active Cdk/cyclin complex and cell cycle progression [33] . In this sense, the Cks 1/FRS2 interaction may provide a mechanism to regulate FGF-mediated mitogenesis [33] . The regulation of this process under conditions in which FRS2 supports a differentiative response is presently not clear.
Despite differences in Cks1 binding, however, FRS2 and FRS3 seem to perform many complementary functions.
Expression of FRS3 in FRS2
−/− mouse fibroblasts for example, reconstitutes FGF-dependent MAPK/ERK activation [19] . Our studies clearly show that FRS3 can function to promote neurite outgrowth. However, over-expression of FRS3 does not synergistically enhance NGF-dependent neurite outgrowth. Recently, a possible anti-mitogenic role for FRS3 has been proposed in that it decreases EGF-induced MAPK/ERK signaling in the osteosarcoma cell line, Saos-2 [38] . Ongoing studies will be directed at determining the consequence of overexpression and/or loss of FRS3 expression on FGF and/or neurotrophin-induced proliferation/differentiation in primary neurons and/or in transgenic mice.
